Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: February 16, 2012
Last updated: NA
Last verified: February 2012
History: No changes posted
This study is conducted in Europe. The aim of the study was to evaluate the safety and efficacy of biphasic insulin aspart 30 (NovoMix® 30) when switching to a modern premix insulin analogue treatment compared to previous insulin regimen in routine clinical practice in the Slovak Republic.

Condition Intervention
Diabetes Mellitus, Type 2
Drug: biphasic insulin aspart 30

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • HbA1c (glycosylated haemoglobin) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Fasting plasma glucose (FPG) [ Designated as safety issue: No ]
  • Post−prandial glucose (PPG) [ Designated as safety issue: No ]
  • Weight [ Designated as safety issue: No ]
  • Hypoglycaemia [ Designated as safety issue: No ]
  • Adverse events [ Designated as safety issue: No ]

Enrollment: 454
Study Start Date: January 2006
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
BIAsp 30 users Drug: biphasic insulin aspart 30
Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any


Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with type 2 diabetes in whom at the discretion of the investigator it was decided to change insulin regimen to biphasic insulin aspart 30

Inclusion Criteria:

  • Subjects with type 2 diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01536639

Bratislava, Slovakia, 811 05
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: M. Suplatova Novo Nordisk Slovakia s.r.o.
  More Information

Additional Information:
Responsible Party: Public Access to Clinical Trials, Novo Nordisk A/S Identifier: NCT01536639     History of Changes
Other Study ID Numbers: BIASP-1929 
Study First Received: February 16, 2012
Last Updated: February 16, 2012
Health Authority: Slovakia: State Institute for Drug Control

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin, Isophane
Biphasic Insulins
Insulin Aspart
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on October 25, 2016